EU/3/19/2144: Orphan designation for the treatment of cystic fibrosis

Poly(N-acetyl, N-arginyl)glucosamine

Table of contents

Overview

On 26 February 2019, orphan designation (EU/3/19/2144) was granted by the European Commission to Accelsiors Ltd, Hungary, for poly(N-acetyl, N-arginyl)glucosamine (also known as PAAG15A or SNSP113) for the treatment of cystic fibrosis.

Key facts

Active substance
Poly(N-acetyl, N-arginyl)glucosamine
Intended use
Treatment of cystic fibrosis
Orphan designation status
Positive
EU designation number
EU/3/19/2144
Date of designation
26/02/2019
Sponsor

Accelsiors CRO and Consultancy Services Ltd
1147 Budapest Xiv
Miskolci Utca 50
Hungary
Tel. +36 1299 0091
E-mail: info@synspira.com

 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating